Przejdź do zawartości
Merck

ADAR1 Transcriptome editing promotes breast cancer progression through the regulation of cell cycle and DNA damage response.

Biochimica et biophysica acta. Molecular cell research (2020-04-11)
Eduardo A Sagredo, Alfredo I Sagredo, Alejandro Blanco, Pamela Rojas De Santiago, Solange Rivas, Rodrigo Assar, Paola Pérez, Katherine Marcelain, Ricardo Armisén
ABSTRAKT

RNA editing has emerged as a novel mechanism in cancer progression. The double stranded RNA-specific adenosine deaminase (ADAR) modifies the expression of an important proportion of genes involved in cell cycle control, DNA damage response (DDR) and transcriptional processing, suggesting an important role of ADAR in transcriptome regulation. Despite the phenotypic implications of ADAR deregulation in several cancer models, the role of ADAR on DDR and proliferation in breast cancer has not been fully addressed. Here, we show that ADAR expression correlates significantly with clinical outcomes and DDR, cell cycle and proliferation mRNAs of previously reported edited transcripts in breast cancer patients. ADAR's knock-down in a breast cancer cell line produces stability changes of mRNAs involved in DDR and DNA replication. Breast cancer cells with reduced levels of ADAR show a decreased viability and an increase in apoptosis, displaying a significant decrease of their DDR activation, compared to control cells. These results suggest that ADAR plays an important role in breast cancer progression through the regulation of mRNA stability and expression of those genes involved in proliferation and DDR impacting the viability of breast cancer cells.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Triptolide, from Tripterygium wilfordii, ≥98% (HPLC), solid
Sigma-Aldrich
MISSION® esiRNA, targeting human ADAR